SC 13G/A: Xilio Therapeutics, Inc.

AI Summary

SC 13G/A filing by Xilio Therapeutics, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securiti

Filing Documents

• tm2428252d3_sc13ga.htm (SC 13G/A) — 99KB
• 0001104659-24-119012.txt ( ) — 101KB

(a)

Item 1(a) Name of Issuer Xilio Therapeutics, Inc. (the “Issuer”)

(b)

Item 1(b) Address of Issuer's Principal Executive Offices 828 Winter Street, Suite 300 Waltham, MA 02451

(a)

Item 2(a) Name of Person Filing This Schedule 13G is filed by (i) Atlas Venture Fund XI, L.P., a Delaware limited partnership (“Atlas XI”), (ii) Atlas Venture Associates XI, L.P., a Delaware limited partnership (“AVA XI LP”), (iii) Atlas Venture Associates XI, LLC, a Delaware limited liability company (“AVA XI LLC” and together with Atlas XI and AVA XI LP, the “Fund XI Reporting Persons”), (iv) Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership (“AVO I”), (v) Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership (“AVAO LP”) and (vi) Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company (“AVAO LLC” and together with AVO I and AVAO LP, the “Opportunity Fund Reporting Persons” and together with the Fund XI Reporting Persons, the “Reporting Persons”).

(b)

Item 2(b) Address of Principal Business Office or, if none, Residence 300 Technology Square, 8th Floor Cambridge, Massachusetts 02139

(c)

Item 2(c) Citizenship Each of Atlas XI, AVA XI LP, AVO I and AVAO LP is a Delaware limited partnership. Each of AVA XI LLC and AVAO LLC is a Delaware limited liability company.

(d)

Item 2(d) Title of Class of Securities Common Stock, $0.0001 par value per share

(e)

Item 2(e) CUSIP Number 98422T100 Item 3 Not applicable. Item 4 Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 (a) Amount beneficially owned: 0 (b) Percent of class: 0.0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 0 CUSIP No. 98422T100 Page 9 of 10 Pages Item 5 If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. Item 6 Not applicable. Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company Not applicable. Item 8 Identification and Classification of Members of the Group Not applicable. Item 9 Notice of Dissolution of Group Not applicable. Item 10 Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. CUSIP No. 98422T100 Page 10 of 10 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 14, 2024 ATLAS VENT

View Full Filing

View this SC 13G/A filing on SEC EDGAR